LONDON — Healthcare communications agency 90Ten has been acquired by global medical communications and technology company Envision Pharma Group.

90Ten will retain its brand and service offering, and the agency will continue to be managed from its London headquarters by the existing management team, including co-founders Paul Tanner, the agency’s chairman, and CEO Carole North, as well as managing directors Peter Impey and Alison Doughty. The terms of the deal have not been revealed.

The partnership will enable Envision Pharma Group to add 90Ten’s behavioral science model, Feel-Think-Do, to its services, which include its iEnvision pharmaceutical compliance platform, strategic publications, medical strategy and communications, market access, and creative and digital.

Envision Pharma Group CEO David Thompson said: “We’re delighted to welcome an award-winning healthcare communications consultancy into the Envision Pharma Group family. 90Ten will add its expertise across new verticals for the group in corporate communications and public relations, while extending Envision’s current footprint in patient engagement and medical communications with its behavioural science methodology.

"This move bolsters our industry-leading scientific communications capabilities, and enables us to strengthen our offering to clients across the product life cycle.”

Tanner said: “Envision Pharma Group will provide global support to accelerate our plans to extend into more markets and reach more audiences. Both companies share the same values, which is reflected in the similarities between our passionate, ambitious, and collaborative teams who are dedicated to improving patient outcomes.”

North added: “We’ve always said, if we partnered with another company it would have to be one that was the right strategic and cultural fit. Envision Pharma Group embodies all of this and will allow us to retain our individuality, culture, and entrepreneurial spirit.”

Based in London, 90Ten employs around 70 people, and works with more than half of the world’s top 20 pharma companies across Europe and North America. The acquisition will bring the total number of Envision Pharma Group employees to around 800 across 14 offices.